The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...

Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...

Novo Nordisk has filed for approval to extend the ... a childhood obesity specialist at the University of Minnesota Medical School in Minneapolis, pointed out that, left untreated, childhood ...

The 'big three' insulin producers Novo Nordisk, Eli Lilly ... Mississippi, and Minnesota. "We're fighting back against drug companies and PBMs that unacceptably and artificially inflate the ...

The Republican-controlled State Senate has joined the DFL-controlled House to advance a proposed emergency insulin bill. In mid-February, the Minnesota Senate established a plan to give ...

Google Maps to rename 'Gulf of Mexico' to 'Gulf of America' for US users United Statescategory· January 28, 2025 Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...